Welcome to CM Online Store!
Antibody Drug Conjugate Kits!
AqT bioconjugates coming soon!
CellMosaic now provides PerKits® to help our life science clients quickly evaluate proteins through the direct conjugation of a range of key payloads (e.g., chemotherapeutic drugs and toxins) using traditional linker chemistry. Kits are available in multiple configurations with a variety of conjugation strategies. CellMosaic protein-drug conjugate (PDC) PerKits® are designed to prepare conjugates via surface amines. Some PDC kits are compatible with general payloads containing specific functional groups, such as carboxylic acids or amines, while others include selected, standard linkage molecules conjugated to a chosen payload. These kits come with the appropriate reactive modifications for directly attaching the payload and linker to the customer’s specific antibody of interest. Each kit includes all necessary reagents and procedures for attaching the selected payload directly to the customer’s antibody and purifying the final PDC. Customers only need to provide their antibody and standard lab equipment.
A typical CellMosaic personalized PDC kit yields approximately 50 nmoles of final PDC in buffer with drug-to-protein ratios (DARs) ranging from 2 to 5, and an average DAR of 3 to 4. Conjugate purities are typically over 90%, with less than 5% free payload. Individual results may vary depending on the specific protein system used and the hydrophobicity of the payload. The kit instructions are comprehensive and easy to follow, with the procedure generally completed within 4 hours and requiring less than 1 hour of hands-on time.
Product# |
Drug |
Mechanism of Action |
Protein |
Labeling Chemistry |
Linkage |
Scale of Reaction (Standard Kit) |
CM11432 | Deruxtecan | Topoisomerase I Inhibitor | Any protein | Surface amine | Releasable (GGFG) | 6.67-20 nmol |
CM11435 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Stable | 6.67-20 nmol |
CM11436 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
CM11430 | SN38 | Topoisomerase I Inhibitor | Any protein | Surface amine | Releasable (ester) | 6.67-20 nmol |
CM11438 | SN38 | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
CM11414 | DM1 | Tubulin Polymerization Inhibitor | Any protein | Surface amine | Stable | 6.67-20 nmol |
CM11439 | PBD Dimer | DNA Binding | Ab or Protein | Surface amine | Releasable (VA) | 6.67-20 nmol |
CM52408 | Acid | N/A (Customer Supplied) | Any protein | Surface amine | Stable | 15-50 nmol |
AqueaTether® TechnologyWhen a drug conjugate cannot be synthesized using classical linkers, or when the effectiveness of the drug conjugate is compromised by the number of toxins loaded onto the antibody, CellMosaic has developed novel, super-hydrophilic, high-loading AqueaTether® (AqT®) linkers to address these challenges. For more information about AqT® technologies, click here. To learn how to access this technology for your novel PDC development, Learn more here. |